Bristol-Myers Squibb, Medivir to collaborate on HIV drug MIV-170

By E. Janene Geiss

Philadelphia, Sept. 13 - Bristol-Myers Squibb Co. and Medivir AB announced Wednesday a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen.

Terms of the agreement include an upfront payment from Bristol-Myers Squibb of $7.5 million to Medivir, the companies said in a news release.

Huddinge, Sweden-based Medivir said it also may receive prespecified development and regulatory milestones totaling about $97 million from the collaboration as well as up to double-digit royalties on sales of the product commercialized under the collaboration.

Under the licensing agreement, Princeton, N.J.-based Bristol-Myers Squibb will be responsible for the worldwide development and commercialization for all countries, excluding the Nordic region, where Medivir has retained the Nordic region commercialization rights.

The MIV-170 project represents a new structural class of NNRTIs. A polymerase inhibitor, MIV-170 has demonstrated excellent potency in vitro and an improved barrier to resistance in preclinical studies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.